Cargando…

Dulce Digital-Me: protocol for a randomized controlled trial of an adaptive mHealth intervention for underserved Hispanics with diabetes

BACKGROUND: By 2034, the number of US individuals with diabetes is predicted to increase from 23.7 to 44.1 million, and annual diabetes-related spending is expected to grow from $113 to $336 billion. Up to 55% of US Hispanics born in the year 2000 are expected to develop diabetes during their lifeti...

Descripción completa

Detalles Bibliográficos
Autores principales: Philis-Tsimikas, Athena, Fortmann, Addie L., Godino, Job G., Schultz, James, Roesch, Scott C., Gilmer, Todd P., Farcas, Emilia, Sandoval, Haley, Savin, Kimberly L., Clark, Taylor, Chichmarenko, Mariya, Jones, Jennifer A., Gallo, Linda C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796443/
https://www.ncbi.nlm.nih.gov/pubmed/35090520
http://dx.doi.org/10.1186/s13063-021-05899-x
_version_ 1784641328869539840
author Philis-Tsimikas, Athena
Fortmann, Addie L.
Godino, Job G.
Schultz, James
Roesch, Scott C.
Gilmer, Todd P.
Farcas, Emilia
Sandoval, Haley
Savin, Kimberly L.
Clark, Taylor
Chichmarenko, Mariya
Jones, Jennifer A.
Gallo, Linda C.
author_facet Philis-Tsimikas, Athena
Fortmann, Addie L.
Godino, Job G.
Schultz, James
Roesch, Scott C.
Gilmer, Todd P.
Farcas, Emilia
Sandoval, Haley
Savin, Kimberly L.
Clark, Taylor
Chichmarenko, Mariya
Jones, Jennifer A.
Gallo, Linda C.
author_sort Philis-Tsimikas, Athena
collection PubMed
description BACKGROUND: By 2034, the number of US individuals with diabetes is predicted to increase from 23.7 to 44.1 million, and annual diabetes-related spending is expected to grow from $113 to $336 billion. Up to 55% of US Hispanics born in the year 2000 are expected to develop diabetes during their lifetime. Poor healthcare access and cultural barriers prevent optimal care, adherence, and clinical benefit, placing Hispanics at disproportionate risk for costly diabetes complications. Mobile technology is increasingly prevalent in all populations and can circumvent such barriers. Our group developed Dulce Digital, an educational text messaging program that improved glycemic control relative to usual care. Dulce Digital-Me (DD-Me) has been tailored to a participant’s individual needs with a greater focus on health behavior change. METHODS: This is a three-arm, parallel group, randomized trial with equal allocation ratio enrolling Hispanic adults with low income and poorly managed type 2 diabetes (N = 414) from a San Diego County Federally Qualified Health Center. Participants are randomized to receive Dulce Digital, Dulce Digital-Me-Automated, or Dulce Digital-Me-Telephonic. The DD-Me groups include Dulce Digital components plus personalized goal-setting and feedback delivered via algorithm-driven automated text messaging (DD-Me-Automated) or by the care team health coach (DD-Me-Telephonic) over a 12-month follow-up period. The study will examine the comparative effectiveness of the three groups in improving diabetes clinical control [HbA1c, primary outcome; low-density lipoprotein cholesterol (LDL-C), and systolic blood pressure (SBP)] and patient-provider communication and patient adherence (i.e., medication, self-management tasks) over 12 months and will examine cost-effectiveness of the three interventions. DISCUSSION: Our comparative evaluation of three mHealth approaches will elucidate how technology can be integrated most effectively and efficiently within primary care-based chronic care model approaches to reduce diabetes disparities in Hispanics and will assess two modes of personalized messaging delivery (i.e., automated messaging vs. telephonic by health coach) to inform cost and acceptability. TRIAL REGISTRATION: NCT03130699-All items from the WHO Trial Registration data set are available in https://clinicaltrials.gov/ct2/show/study/NCT03130699. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05899-x.
format Online
Article
Text
id pubmed-8796443
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87964432022-02-03 Dulce Digital-Me: protocol for a randomized controlled trial of an adaptive mHealth intervention for underserved Hispanics with diabetes Philis-Tsimikas, Athena Fortmann, Addie L. Godino, Job G. Schultz, James Roesch, Scott C. Gilmer, Todd P. Farcas, Emilia Sandoval, Haley Savin, Kimberly L. Clark, Taylor Chichmarenko, Mariya Jones, Jennifer A. Gallo, Linda C. Trials Study Protocol BACKGROUND: By 2034, the number of US individuals with diabetes is predicted to increase from 23.7 to 44.1 million, and annual diabetes-related spending is expected to grow from $113 to $336 billion. Up to 55% of US Hispanics born in the year 2000 are expected to develop diabetes during their lifetime. Poor healthcare access and cultural barriers prevent optimal care, adherence, and clinical benefit, placing Hispanics at disproportionate risk for costly diabetes complications. Mobile technology is increasingly prevalent in all populations and can circumvent such barriers. Our group developed Dulce Digital, an educational text messaging program that improved glycemic control relative to usual care. Dulce Digital-Me (DD-Me) has been tailored to a participant’s individual needs with a greater focus on health behavior change. METHODS: This is a three-arm, parallel group, randomized trial with equal allocation ratio enrolling Hispanic adults with low income and poorly managed type 2 diabetes (N = 414) from a San Diego County Federally Qualified Health Center. Participants are randomized to receive Dulce Digital, Dulce Digital-Me-Automated, or Dulce Digital-Me-Telephonic. The DD-Me groups include Dulce Digital components plus personalized goal-setting and feedback delivered via algorithm-driven automated text messaging (DD-Me-Automated) or by the care team health coach (DD-Me-Telephonic) over a 12-month follow-up period. The study will examine the comparative effectiveness of the three groups in improving diabetes clinical control [HbA1c, primary outcome; low-density lipoprotein cholesterol (LDL-C), and systolic blood pressure (SBP)] and patient-provider communication and patient adherence (i.e., medication, self-management tasks) over 12 months and will examine cost-effectiveness of the three interventions. DISCUSSION: Our comparative evaluation of three mHealth approaches will elucidate how technology can be integrated most effectively and efficiently within primary care-based chronic care model approaches to reduce diabetes disparities in Hispanics and will assess two modes of personalized messaging delivery (i.e., automated messaging vs. telephonic by health coach) to inform cost and acceptability. TRIAL REGISTRATION: NCT03130699-All items from the WHO Trial Registration data set are available in https://clinicaltrials.gov/ct2/show/study/NCT03130699. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05899-x. BioMed Central 2022-01-28 /pmc/articles/PMC8796443/ /pubmed/35090520 http://dx.doi.org/10.1186/s13063-021-05899-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Philis-Tsimikas, Athena
Fortmann, Addie L.
Godino, Job G.
Schultz, James
Roesch, Scott C.
Gilmer, Todd P.
Farcas, Emilia
Sandoval, Haley
Savin, Kimberly L.
Clark, Taylor
Chichmarenko, Mariya
Jones, Jennifer A.
Gallo, Linda C.
Dulce Digital-Me: protocol for a randomized controlled trial of an adaptive mHealth intervention for underserved Hispanics with diabetes
title Dulce Digital-Me: protocol for a randomized controlled trial of an adaptive mHealth intervention for underserved Hispanics with diabetes
title_full Dulce Digital-Me: protocol for a randomized controlled trial of an adaptive mHealth intervention for underserved Hispanics with diabetes
title_fullStr Dulce Digital-Me: protocol for a randomized controlled trial of an adaptive mHealth intervention for underserved Hispanics with diabetes
title_full_unstemmed Dulce Digital-Me: protocol for a randomized controlled trial of an adaptive mHealth intervention for underserved Hispanics with diabetes
title_short Dulce Digital-Me: protocol for a randomized controlled trial of an adaptive mHealth intervention for underserved Hispanics with diabetes
title_sort dulce digital-me: protocol for a randomized controlled trial of an adaptive mhealth intervention for underserved hispanics with diabetes
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796443/
https://www.ncbi.nlm.nih.gov/pubmed/35090520
http://dx.doi.org/10.1186/s13063-021-05899-x
work_keys_str_mv AT philistsimikasathena dulcedigitalmeprotocolforarandomizedcontrolledtrialofanadaptivemhealthinterventionforunderservedhispanicswithdiabetes
AT fortmannaddiel dulcedigitalmeprotocolforarandomizedcontrolledtrialofanadaptivemhealthinterventionforunderservedhispanicswithdiabetes
AT godinojobg dulcedigitalmeprotocolforarandomizedcontrolledtrialofanadaptivemhealthinterventionforunderservedhispanicswithdiabetes
AT schultzjames dulcedigitalmeprotocolforarandomizedcontrolledtrialofanadaptivemhealthinterventionforunderservedhispanicswithdiabetes
AT roeschscottc dulcedigitalmeprotocolforarandomizedcontrolledtrialofanadaptivemhealthinterventionforunderservedhispanicswithdiabetes
AT gilmertoddp dulcedigitalmeprotocolforarandomizedcontrolledtrialofanadaptivemhealthinterventionforunderservedhispanicswithdiabetes
AT farcasemilia dulcedigitalmeprotocolforarandomizedcontrolledtrialofanadaptivemhealthinterventionforunderservedhispanicswithdiabetes
AT sandovalhaley dulcedigitalmeprotocolforarandomizedcontrolledtrialofanadaptivemhealthinterventionforunderservedhispanicswithdiabetes
AT savinkimberlyl dulcedigitalmeprotocolforarandomizedcontrolledtrialofanadaptivemhealthinterventionforunderservedhispanicswithdiabetes
AT clarktaylor dulcedigitalmeprotocolforarandomizedcontrolledtrialofanadaptivemhealthinterventionforunderservedhispanicswithdiabetes
AT chichmarenkomariya dulcedigitalmeprotocolforarandomizedcontrolledtrialofanadaptivemhealthinterventionforunderservedhispanicswithdiabetes
AT jonesjennifera dulcedigitalmeprotocolforarandomizedcontrolledtrialofanadaptivemhealthinterventionforunderservedhispanicswithdiabetes
AT gallolindac dulcedigitalmeprotocolforarandomizedcontrolledtrialofanadaptivemhealthinterventionforunderservedhispanicswithdiabetes